|
Cohort1: Avacincaptad Pegol
|
| Administration route |
intravitreal injection |
| Dosage |
avacincaptad pegol, 2mg, Monthly through Month 11 |
| Pts |
225 |
| Age |
Adult, Older_Adult |
| Outcome |
Mean Rate of Change in GA Over 12 Months (Measured at Three Time Points: Baseline, Month 6, and Month 12):Least Squares Mean (Standard Error):0.336(0.032) |
| Adverse reactions |
2/225(All-cause mortality); 30/225(Cardiac disorders; Eye disorders; Gastrointestinal disorders; Hepatobiliary disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
| References |
PMID:
37696275
|
|
|
Cohort2: sham administration
|
| Administration route |
intravitreal injection |
| Dosage |
sham administration, Monthly through Month 11 |
| Pts |
222 |
| Age |
Adult, Older_Adult |
| Outcome |
Mean Rate of Change in GA Over 12 Months (Measured at Three Time Points: Baseline, Month 6, and Month 12):Least Squares Mean (Standard Error):0.392(0.033) |
| Adverse reactions |
1/222(All-cause mortality); 37/222(Cardiac disorders; Congenital, familial and genetic disorders; Eye disorders; Gastrointestinal disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Product Issues; Reproductive system and breast disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
| References |
PMID:
37696275
|
|